Abstract:Hepatocellular carcinoma (HCC) is a common malignant tumor worldwide, with high morbidity and mortality. Chronic infection with hepatitis B virus (HBV) is a major risk factor for the development of hepatocellular carcinoma and the majority (~80%) of hepatocellular carcinoma patients in China exhibit co-morbidity with HBV-associated liver cirrhosis. The goal of reliable early diagnostic and prognostic techniques for HBV-associated HCC remains unrealized. The aim of the present study was to explore the efficacy of serum high-sensitivity C-reactive protein (hs-CRP) tests in the early diagnosis of HCC in patients with HBV-associated liver cirrhosis. A cohort of 493 patients with HBV-associated liver disease was divided into three groups: Chronic HBV (CHB) group; liver cirrhosis without HCC (LC) group; and liver cirrhosis with HCC (HCC) group. A further 47 healthy individuals comprised the healthy control (CN) group. Comparative analyses of clinical symptoms, histopathology, ultrasound imagery, computed tomography, magnetic resonance imaging, biochemistry [α-fetoprotein (AFP) and liver function enzymes], and hs-CRP tests were conducted across these four groups. Immunohistochemical analysis showed that CRP is strongly expressed in HCC tumor tissue, but is not expressed elsewhere. Analyses of the correlations between serum hs-CRP levels and HCC clinical parameters indicated that there was no correlation between serum hs-CRP levels, tumor Edmondson grade, tumor-node-metastasis stage and AFP status. Serum hs-CRP and AFP levels were found to be significantly elevated in the HCC group compared to those in the LC, CHB and CN groups (P<0.01). Receiver operator characteristic analysis showed that measurement of serum hs-CRP could differentiate HCC from HBV-associated liver cirrhosis, as well as increase the accuracy of HCC diagnoses. Additionally, measurement of hs-CRP and AFP together improved diagnostic accuracy for HCC compared with either test alone. Serum hs-CRP could have potential as an effective diagnostic tool to complement AFP in diagnosing HCC and improving the identification of AFP-negative HCC in patients with HBV-associated liver cirrhosis. The present findings may facilitate the earlier diagnosis of hepatocellular carcinoma, permitting more effective treatment and a broader spectrum of treatment modalities for patients with advanced hepatic disease.

The level of serum VCAM-1 in patients with primary hepatocellular carcinoma and its clinical significance

Serum Slcam-1 Levels in Patients with Hepatitis B and HBV-related Liver Diseases

Serum Vascular Endothelial Growth Factor is a Predictor of Invasion and Metastasis in Hepatocellular Carcinoma.

Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma

Diagnostic and Prognostic Roles of Serum Vitronectin in Hepatitis B-related Hepatocellular Carcinoma

Diagnostic value of serum vascular endothelial growth factor and interleukin-17 in primary hepatocellular carcinoma

The Value of Serum Glypican-3 Level in Aided Diagnosis of Patients with Primary Hepatocellular Carcinoma

Serum CD166: a Novel Hepatocellular Carcinoma Tumor Marker.

Serum interleukin-18 as a prognostic factor for hepatocellular carcinoma patients

Serum Levels of Extracellular Matrix Protein 1,MMP-9 and VEGF in Patients with Hepatocellular Carcinoma

The Prognostic Significance of Preoperative Serum Levels of Extracellular Matrix Protein 1 in Patients with Hepatocellular Carcinoma

Analysis of Serum Hepatitis B Virus and Hepatitis C Virus Infection Markers in Patients with Primary Carcinoma of Liver

Serum Levels of Macrophage Migration Inhibitory Factor in Patients with Hepatocellular Carcinoma and Its Clinical Significance

Expression and Clinical Significance of CD146 and VEGF in Hepatocellular Carcinoma

Assessment of High-Sensitivity C-reactive Protein Tests for the Diagnosis of Hepatocellular Carcinoma in Patients with Hepatitis B-associated Liver Cirrhosis

Clinical Value of Assessing Serum Levels of Inflammatory Cytokines in the Early Diagnosis of Patients with Primary Liver Carcinoma: a Retrospective Observational Study

Clinical application of joint detection of three serological markers in patients with primary hepatocellular carcinoma before and after percutaneous microwave coagulation therapy

Clinical Signification on CD44 Express of Peripheral Blood Cells in Pat ients with Primary Hepatic Carcinoma

Combined Detection of Serum Tumor Markers in the Diagnosis of Primary Hepatocellular Carcinoma

Significance of the Changes in Serum Soluble Intercellular Adhesion Molecule-1 in Patients with Hepatocellular Carcinoma Before and after TACE